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Abstract 
The Changing Face of Craniopharyngioma Treatment in 
Young Children and its Challenges at a single Centre in a 
developing World Context. 
Objective: To retrospectively review our institutional experience with the 
treatment of paediatric craniopharygiomas and assess the evolution in 
management and influence on patient outcomes. 
Patients and Methods: A retrospective review from January 1995 to 
December 2015 of children age <14 treated at a single institution. Data 
collected included admission clinical features, endocrine function, surgery 
performed, surgical outcome, intracystic therapy and radiotherapy. Long-term 
functional outcome was calculated considering hormonal dependence, level of 
independence and schooling. 
Results: There were 41 patients with a mean age of 84.2 months: 57% were 
female. Primary surgical resection was performed in 36 patients: 80.5% had 
subtotal resection, 11% had gross total resection and the rest had biopsy 
only. Of surgical approaches, 60,7% had pterional craniotomy and 39,2% 
supraorbital keyhole craniotomy. No surgical mortalities occurred but 2 
patients had new post-operative neurological deficits. Stereotactic placement 
of intracystic catheters transitioned to endoscopic. Intracystic treatments 
transitioned from Yttrium (1) to Bleomycin (6) to Interferon Alpha (6). 
Radiotherapy was given in 30 patients, median dose 54Gy. Final Wen 
functional outcome was 21,8% Class I, 32% Class II and 46% Class III. There 
were no early deaths in the series but 5 patients died more than 6 years after 
diagnosis, mostly due to endocrine crises from poor chronic care. 
Conclusion: The findings reflect a multidisciplinary team approach consisting 
of maximal safe resection with radiotherapy, intracystic agents and endocrine 
support. For a cohort limited to young children, our results are similar in 
number and outcomes to other published series. Mortality remains low but 
lifelong dependence on endocrine replacement is a significant contributor to 
long-term morbidity and mortality. This has important implications for patients 
referred from large distances and where primary and secondary follow up 
care is poor. 
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Section A 
 
Background/ The Setting 
 
Craniopharyngiomas are benign brain tumours arising from the middle skull 
base, related to the pituitary gland and infundibulum. Epidemiology and 
demographic patterns are poorly described because the disease is rare. 
Furthermore, brain tumour registries largely collect data for malignant tumours 
and leave many lesions under reported. Our understanding of these tumours 
is derived from first world literature, from non-African population groups who 
are exposed to different resources.  
In South Africa, due to the enormous burden of communicable diseases and 
trauma within an emerging economy, primary health care is the focus of 
resource investment. Brain tumours fall under tertiary health care. Such 
tertiary centres are the most resource intensive, requiring specialists and 
specialized equipment, leading to centralization. No more than two or three 
are accommodated in a province. This structuring presents challenges to the 
management of brain tumour patients. People have to travel large distances 
to access needed health care, access to follow up is difficult. Management 
prescriptions and approaches that require close patient monitoring become 
difficult. For example, a patient treated with surgical resection only and no 
radiation therapy will require repeat hospital visits to monitor for recurrence. 
Given the difficulties with follow up and access, should this risk be taken, 
given the possibility of loss to follow up and late presentation with 
unsalvageable recurrence? Or should all receive preventative radiation 
therapy with all its attendant risks to protect against such loss to follow up? 
These questions may be less important in high-income countries but must be 
considered when resources are constrained. These factors have implications 
for treatment and so a local analysis of practices and outcome is needed. 
 
Craniopharyngioma is a useful example of a tertiary care driven condition to 
examine for several reasons. First, dedicated specialised services in skills and 
equipment are needed. Experienced paediatric neurosurgeons are ideal if 
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possible. In addition to expertise, they require tools - microsurgical and 
endoscopic and occasionally navigation. Similarly, radiotherapy services are 
essential and must be accessible. Endocrine support is also critical. Following 
on this, a multidisciplinary approach to decision-making is essential. Ideally, 
there should be a multidisciplinary clinic that jointly manages children and 
decides on priorities. Finally, this is a chronic condition that often presents in 
childhood but has to be actively managed over many years of life expectancy. 
Understandably, there are several challenges to meeting these requirements 
in a developing world setting.  
 
For the above reasons, we aimed to examine the treatment and outcomes of 
young children with craniopharyngioma in a single centre in South Africa to 
characterise the patient population, describe their treatment outcomes and 
identify factors that may be challenges in the developing world context. 
 
We aimed to examine young children (age 13 or less) who presented for 
treatment. In part this represents the patient population that presents to the 
Red Cross Children’s Hospital, and in part it reflects the patient population 
managed through the multidisciplinary clinic. The age range is particularly 
important when comparing to published series, most of which include children 
up to age 16 or 21, and/or adults.  
 
Overview of the thesis and Layout 
Chapter 1: A review of current knowledge about craniopharyngiomas is 
discussed presenting understanding of relevant anatomy and embryological 
origins. It discusses how treatments have changed over the years. A 
summary analysis of reported outcomes on overall mortality and specifically 
perioperative mortality has been performed and presented. Important issues 
around clinical presentation, hormonal deficiencies and attempts to 
characterise tumour related features that influence treatment and outcome. 
We review the history and evolution of oncological management including 
intracystic therapy, radiation oncology techniques and how these have 
influenced the approach to surgical resection.  
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Chapter 2 
This chapter presents our results and is divided into sections that cover 
important stages in the management of craniopharyngioma patients, along 
with observations that may have an influence on outcome. Surgical results 
and their influence on morbidity are reported independently, followed by 
endocrine and oncological findings. An attempt is then made to classify 
survivors according to the level of function to determine an overall picture of 
the influence of treatment on outcome.  
 
Methodology Overview 
This was a retrospective folder review. Sources of data included databases 
from neurosurgery, radiation oncology, endocrinology and radiology. Further 
details are included in chapter 2. 
Due to the rarity of these tumours, meaningful information could be obtained 
only from long-term experience. The time span was 20years up to and 
including 31 December 2015. Although literature defines paediatric as age 
<19, our definition was age <14, reflecting the admission age limit at Red 
Cross Children’s Hospital. Because craniopharyngioma is a benign lesion with 
long term survival but compromised quality of life, data capture focused on 
indexes that would reflect that quality of life, endocrine status, surgery type 
and radiation oncology.  
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Chapter 1  
 
Introduction and Literature Review 
 
Craniopharyngiomas are rare epithelial tumours of the parasellar region, 
thought to arise from remnants of Rathke’s pouch along the path of the 
craniopharyngeal duct. Although benign with high survival rates, the quality of 
life (QOL) in these patients is frequently poorer than the general population. 
This is a function of both tumour location and treatment sequelae. 
Craniopharyngiomas have two distinct histological subtypes: the 
adamantinomatous type, common in children, frequently cystic with 
calcifications and the papillary subtype, occurring exclusively in the adult 
population. Evidence suggests that these tumours are biologically and 
embryologically distinct. 
 
History:  
The first description of a craniopharyngioma was in 1857 by the pathologist 
Friedrich von Zenker, from an autopsy case. Already by this time Martin 
Rathke had described embryological origin of the pituitary gland from the 
anterior foregut (1). The term craniopharyngioma was coined by Charles 
Frazier and popularized by Harvey Cushing, but Halstead was the first to 
successfully resect these tumours. Over the course of the 20th century, 
operative management of these lesions evolved from aggressive surgery with 
dismal outcomes to slight improvement with the introduction of corticosteroids, 
penicillin and the operating microscope(2). Matson and Ingraham were among 
the first to describe outcomes with perioperative corticosteroid 
administration(3). Further improvements in patient outcomes were aided by 
introduction of computerized tomography (CT) In 1974, the resurgence of 
endoscopic surgery to the modern microsurgical era, peaking in the 90’s. 
Modern strategies such as radiation therapy and intratumoral chemotherapy 
have transformed craniopharyngioma care from a mortality prevention 
strategy to quality of life preservation objective. 
	 5	
 
Table 1: summary of overall mortality over eight decades in surgical series. A 
trend of decreasing mortality is seen reflecting improved therapies. 
 
A progressive decrease in perioperative mortality has been seen over the past 
seven decades as neurosurgical techniques have improved in sophistication. 
Microsurgery was introduced into neurosurgery in 1967(4). After this, 
advocates of radical tumour extirpation grew. Endoscopic surgery brought 
increased safety and improved morbidity. Table 2 summarizes these 
outcomes through an analysis of published surgical reports. Only those that 
reported perioperative mortality, defined as death within thirty days of surgery 
were included. Many studies combined paediatric and adult data, this could 
not be separated on analysis. Mortality at primary and reoperations in each 
study were grouped into a single final outcome. 
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. 
 
Table 2: Forest plot demonstrating perioperative mortality in the decades 
following Cushing’s report on his experience in 1932 
 
Epidemiology: 
Craniopharyngiomas account for 3% of brain tumours overall but 10% of 
paediatric brain tumours and are the most common suprasellar tumour in the 
paediatric population(5). No data exists from South Africa and statistics from 
the National Cancer Registry do not specify brain tumour subtype. 
Internationally, the incidence is 0,13 per 100,000 per year and does not vary 
by gender(6). There is a bimodal age distribution with a peak in children (5-
14years) and adults (65-74years). Survival is higher among children although 
comparison is difficult due to difference in tumour subtype. 
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Embryology:  
Craniopharyngiomas arise from the pituitary stalk, thus the embryological 
origin follows the development of the pituitary gland and stalk. The pituitary 
gland develops from two distinct parts of the embryo. The posterior pituitary or 
neurohypophysis originates as a downward growth of neural tissue from the 
floor of the diencephalon, as the infundibulum. This begins in week 4. 
Simultaneously, the roof of the primitive oral cavity or stomodeum develops a 
dorsal diverticulum, anterior to the buccopharyngeal membrane. This dorsal 
evagination of the stomodeum is termed Rathke’s pouch. This pouch ascends 
through chondrification centers of the developing sphenoid bone and 
connects with the anterior and lateral surfaces of the descending 
infundibulum(7). The path taken by the Rathke’s pouch is termed the 
craniopharyngeal duct. 
Two theories have been postulated to explain the pathogenesis of 
craniopharyngiomas, namely the Embryogenic theory and Metaplastic theory. 
• Embryogenic theory: this hypothesis suggests that embryogenic 
squamous cell nests along the path of the involuted craniopharyngeal 
duct undergo neoplastic transformation. This theory is supported by the 
typical microscopic composition of calcifying squamous epithelium that 
resembles odontogenic tumours. 
• Metaplastic theory: Residual squamous epithelium in the 
adenohypophysis and anterior infundibulum undergoes neoplastic 
transformation. This theory suggests that tumours arise from 
metaplasia of mature components of the anterior pituitary, rather than 
embryonic remnants(8).  
It is likely that these theories simply describe the two varieties of 
craniopharyngioma. The adamantinomatous variety, largely cystic, with 
calcification most closely resembling odontogenic tumours probably fits into 
the embryogenic theory. The exclusively adult papillary tumour, infrequently 
calcifying or cystic is likely accounted for by the metaplastic theory. This adds 
to the idea that, although these lesions share a common name, they should 
be treated as distinct clinical and biological entities. 
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Pathology and Molecular Oncogenesis:  
Craniopharyngiomas are histologically benign World Health Organisation 
(WHO) Grade I lesions(9). The adamantinomatous tumours occur at both age 
peaks but most frequent in children. Macroscopically, they vary from 
predominantly solid, to entirely cystic in 15% of cases or more commonly in 
70% of cases partially cystic and solid(10). The cystic fluid varies in 
appearance from dark “machine-oil” like, to shimmering yellow. This fluid 
contains desquamated epithelial cells and cholesterol crystals. The majority of 
these lesions (80%) have calcifications. Microscopically, the tumours 
resemble adamantinoma of the jaw and calcifying odontogenic cyst(11). They 
have trabeculae of squamous epithelium with clusters of wet keratin. 
Papillary variants occurring exclusively in adults are frequently solid with just 
over 50% having cystic components and 45% have calcifications. 
Microscopically they have solid sheets of squamous epithelium with 
fibrovascular stroma. They may have foci of cilliation and goblet cells, wet 
keratin is characteristically absent(12)(13).  
 
Genetic and molecular characterization of these tumours has been hampered 
by their rarity. It is recognized however that chromosomal deletions, 
amplifications and translocations play an important role in tumour genesis. 
Papillary craniopharyngiomas have demonstrated no recurrent mutations to 
implicate in their genesis. Vascular Endothelial Growth Factor (VEGF) 
expression increase is present but not unique to these tumours. P53 tumour 
suppressor gene mutations are absent(14). More promising results have 
come from the demonstration that adamantinomatous craniopharyngiomas 
have intracellular accumulation of β-catenin(15). Beta-catenin is a dual 
function protein and a downstream component of the Wnt signal transduction 
pathway. This is involved in regulation of cellular proliferation, morphology 
and development. Genes encoding β-catenin, Catenin Beta 1 (CTNNB1) and 
Adenomatous Poliposis Coli (APC) are characteristic only in the 
adamantinomatous variant(16)(17)(18)(12)(19). 
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Natural History and Clinical Difficulties: 
Although histologically benign, these tumours can have an aggressive clinical 
course. Craniopharyngiomas are lifelong afflictions with a tendency to recur. 
The rate of recurrence increases with duration of follow up. The principal 
difficulty is a result of location. The most frequent site of occurrence is the 
suprasellar space.  Here the tumour is in close proximity to neural and 
vascular structures that are sensitive to treatment effects. Adherence to the 
pituitary stalk and hypothalamus is frequent, increasing the risk of organ 
dysfunction from pressure effects of the tumour and injury with treatment 
modality. The pituitary gland, optic chiasm are also commonly distorted. 
Vascular structures surrounding the lesions include the basal circle of Willis 
and the cavernous sinuses. Consequently, vision, endocrine and 
neurobehavioural function are at risk in the patient. 
 
Clinical Manifestation 
Presentation of craniopharyngioma is determined by the location, size and 
direction of growth. Symptoms vary from non-specific signs of raised 
intracranial pressure, visual impairment to overt coma from hydrocephalus. 
Behavioural and cognitive dysfunction, including decline in scholastic 
performance may also be presenting features. Only a minority of patients 
seek medical help from an endocrine related complaint, even though these 
are frequent abnormal findings(20). The most common presenting complaint 
is non-specific headache and nausea. Symptoms of raised intracranial 
pressure occur more frequently in children than in adults. In a retrospective 
series of 121 paediatric and adult craniopharyngiomas, Karavitaki et al 
reported headache as the dominant presenting complaint in 64% of patients. 
Van Effenterre and colleagues, in their series reported headache as the 
second most common presenting complaint at 53%, after visual deficits which 
were present in 75% of patients(21,22). In this same series, decreased visual 
acuity was documented in 80% of patients, while field deficits were present in 
79%. The median time delay from symptom onset to diagnosis is reported at 
12-27months(8). 
 
	 10	
Endocrine dysfunction at presentation is present in up to 90% of patients. 
Growth hormone (GH) deficiency is the most frequent, occurring in 80-100% 
of patients. Hypogonadism occurs in 75-80%, adrenocorticotrophic hormone 
(ACTH) deficiency 30-60% and hypothyroidism is found in 20-40% of patients. 
The most infrequent is diabetes insipidus, being found in only 7-20% of 
patients(23,24). Pathological reduction in growth velocity is also seen in 
approximately 33% of craniopharyngioma patients, while weight gain 
frequently manifests after treatment(25). Cognitive decline in adults and 
deteriorating school performance in children is not an infrequent complaint at 
presentation. Ocular motor neuropathy and limb weakness in the absence of 
hydrocephalus are uncommon. 
 
Diagnosis and Imaging 
The combination of headache, poor vision, decreased growth rate and cystic 
suprasellar mass can be clinically diagnostic of craniopharyngioma. 
Imaging evaluation is with computed tomography (CT) and magnetic 
resonance imaging (MRI), which are complementary. X-ray, which can show 
calcifications in and around the sella is not routinely utilized.  
CT – this is frequently the screening modality in symptomatic patients. This 
also is the principal diagnostic and follow up modality for hydrocephalus. It 
should be performed with and without contrast administration. The bone 
window will reveal calcifications which are present in 90% of paediatric 
craniophanygniomas, this number drops to 45-50% in adults. The sella turcica 
is frequently not expanded, unlike in pituitary macroadenomas. There may be 
erosion of the dorsum sellae or expansion with calcific rim. Cysts are 
isodense to cerebrospinal fluid (CSF) on CT and the solid component 
enhances in the majority(26).  
 
MRI is the most important imaging modality. It is valuable in diagnosis, 
planning of appropriate therapeutic strategy, early post-operative evaluation of 
extent of resection and in assessment for recurrence. Multiplanar T1 weighted 
images with gadolinium are essential. These delineate the enhancing solid 
component, frequently in the sella with a suprasellar cyst(27). 
Craniopharyngiomas are commonly T1 hyperintense, the cyst may have 
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heterogenous intensity related to protein and cholesterol content. T1 fat 
suppressed image will reveal the posterior pituitary bright spot. In small 
tumours, the gland can be differentiated from the tumour. It is often 
compressed within the sella(28). 
 
Various imaging-based criteria have been proposed to classify location and 
growth of craniopharyngiomas with the view of predicting clinical outcome and 
extent of surgical resection. The relationship of the tumour to the wall of the 
third ventricle is most important surgically. This determines the resectability of 
a tumour and expected morbidity. Many attempts have been made to classify 
these growth patterns. Table 3 and 4 summarize descriptions of growth 
patterns and predictors of hypothalamic involvement(29). Determination of 
tumour size is important because it is correlated to recurrence rate and extent 
of resection. Tumours greater than 5cm have an 80% recurrence rate while 
those less than 5cm a 20% recurrence rate(28). Sainte-Rose et al, in their 
study of surgical management of craniopharyngiomas determined that 
surgical treatment should be guided by preoperative hypothalamic 
involvement(30). Yasargil and later Zuccaro, further classified tumours 
according to size. Small were tumours <2cm, moderate 2-4cm, large 4-6cm 
and giant those greater than 6cm(4,31). 
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Table 3: summary of classification systems for hypothalamic 
involvement(30,32,33) 
 
Table 4: classification systems of tumour growth patterns(4,34,35) 
Hoffman	(1977)		Type	A	Type	B	Type	C		Type	D		Samii	(1997)		Grade	I	Grade	II	Grade	III	Grade	IV	Grade	V		Yasargil	(1990)		Type	a	Type	b	Type	c	Type	d	Type	e	Type	f	
		Sellar	Chiasmatic	Third	ventricle	floor	(pre	and	retrochiasmatic)	Intraventricular				Intrasellar	/	infradiaphragmatic	Occupying	suprasellar	cistern	Lower	half	of	third	ventricle	Upper	half	of	third	ventricle	Reaching	septum	pellucidum	or	lateral	ventricles			Purely	intrasellar	/infradiaphragmatic	Intra	and	suprasellar		Supradiaphragmatic,	paraventricular	Intra/extraventricular	Paraventricular	in	respect	to	v3	Purely	intraventricular	
Grade		 Description		De	Vile	(1996)	0	1	2	3	4	5		Sainte-Rose	(2005)	Type	0	Type	1	Type	2		Puget	(2007)	Grade	0	Grade	1	Grade	2	
		No	visible	damage	V3	floor	thickened	V3	floor	thinned	or	distorted	Small	breach	in	tuber	cinereum	More	extensive	breach	than	grade	3	Floor	of	third	ventricle	completely	deficient			No	involvement	of	hypothalamus	Hypothalamus	elevated	/	distorted	but	visible	Hypothalamus	involved	and	no	longer	visible			No	hypothalamic	involvement	Tumour	abuting	or	displacing	hypothalamus	Hypothalamus	no	longer	identifiable	
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Principles of Management 
The decision-making process in primary treatment of craniopharyngiomas is 
influenced by many factors. Patient, tumour and treatment related 
considerations determine the optimal strategy. Sometimes, prior to addressing 
the tumour, hydrocephalus may be an emergency requiring attention. Surgery 
is nearly always performed, but multimodality interdisciplinary management is 
still the cornerstone of care and must be individualized(36). Options vary from 
limited to radical surgery, influenced by characteristics of the tumour (size, 
consistency, location), the age and clinical state of the patient, as well as 
surgeon experience and training. In cystic tumours, intra-cystic chemotherapy 
is an attractive option, particularly in the very young, with limited morbidity 
associated with insertion and modern agents.  
 
Radiation therapy has emerged as a safe and indispensable tool for long-term 
control. Conventional fractionated external beam radiotherapy, precision 
stereotactic fractionated radiotherapy and radiosurgery have improved 
accuracy and safety. Heavy particle therapy with protons has been studied to 
improve radiobiological profile and outcomes(37–41). 
 
Surgery 
The goals of surgery include biopsy, resection (total and subtotal) and 
insertion of catheters for intra-tumour therapy. Insertion of catheters to 
decompress neural structures and instil intra-cystic chemotherapy can be 
done open via a craniotomy, stereotactically with a bur hole and through 
endoscopic assisted surgery. Resective surgery has evolved from proponents 
of aggressive resection, to a more contemporary approach of limited surgery 
with adjuvant radiation therapy(4,31,42,43). This move has been influenced 
by long term outcome data that supports sustained tumour control and 
preserved QoL with radiation therapy(44–46). Surgical approaches may be 
endoscopic, utilising the trans-sphenoidal route, or transcranial, namely 
pterional and supraorbital key-hole craniotomies that utilize the subfrontal 
corridor. The former also allows a trans-sylvian corridor. Considerations in 
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surgical approach include size, extent and location of the tumour relative to 
the optic chiasm. Pre-chiasmatic tumours are easily accessible through the 
subfrontal corridor while retrochiasmatic tumours are reached with some 
difficulty thought this route. Retro-chiasmatic tumours are also more likely to 
invade the hypothalamus. The extent of resection is classified into biopsy, 
subtotal and gross total resection (GTR). Size >4cm and retrochiasmatic 
extension has been associated with limited GTR(47). Distinction also exists 
between planned subtotal and that occurring with initial intent to GTR. 
 
Radiation Therapy 
There has been a growing shift towards limited surgery and planned adjuvant 
radiation therapy for craniopharyngiomas. Evidence has shown comparable 
tumour control rates with limited surgery and radiation therapy, along with a 
favourable QoL outcome(48). A report by Merchant et al on the St Jude 
Hospital experience showed that children who received radical surgery lost 
9.8 full scale IQ points vs 1.25 points in a limited surgery and radiotherapy 
group (p<0.063)(49). A recent systematic review on predictive factors for 
recurrence in craniopharyngioma noted the presence of residual tumour and 
skipping radiation therapy to be risk factors(50). In the multicentre, 
prospective surveillance Kraniopharyngeom 2000 study, risk of progression at 
3years was 80% lower In irradiated children(51). All modalities have been 
studied including fractionated conventional and stereotactic radiotherapy, 
intensity modulated radiotherapy used to shape beams and conform to the 
lesion, as well as radiosurgery(52–55).  
 
Intracystic Therapies 
Local radiotherapy or brachytherapy with β-emitting isotopes is now of 
historical interest. Substances used were Yttrium-90, phosphorus-32, 
rhenium-186. Characteristics of these agents were low tissue penetration with 
favourable half-life. Phosphorus-32 has a half-life of 14.3days with tissue 
penetration of 2-8mm, Yttrium-90 has 2.7day half–life and 11mm tissue 
penetration(56). Recurrence and survival rates were however inferior to 
surgery and radiation therapy(57). 
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Bleomycin: this is an antitumoral glycopeptide antibiotic used to treat 
squamous cell carcinoma. Due to the epithelial component of childhood 
craniopharyngioma, efficacy in these tumours was suggested as likely. 
Therapeutic benefit with this agent is derived from the control of cyst growth 
but not solid tumour. It does not penetrate the blood brain barrier thus cannot 
be administered systemically. Its effects are on the G, M and S phases of the 
cell cycle(58). Though used widely and effectively in tumour cyst control, 
toxicity and hypothalamic injury from leakage have influenced a move to other 
agents(59)(60). 
Interferon Alpha: Ifα is also a tumour sclerosing agent used in squamous cell 
carcinoma. It is currently the agent of choice for intra-cystic therapy. It has 
excellent cyst growth control and reported to be well tolerated if there is 
ventricular leakage(61–63).  
 
Functional Outcomes after Treatment 
With sophistication of treatment modalities, long-term survival occurs in the 
majority of patients. Survival rates at 3 years, 5 years and 10 years are 97%, 
96% and 93% respectively(51). The quality of that survival has become the 
principal objective. 
Endocrine effects: As stated, admission endocrine deficits are present in up to 
85% of patients, growth Hormone deficiency being the most common. 
Restoration of previously deficient hormones is exceptionally rare. The extent 
of surgery has the strongest influence on new endocrine dysfunction. 
Transient post-operative diabetes insipidus (DI) occurs in nearly 100% of 
patients. Permanent (DI) occurs in 80-93% of patients who undergo GTR, GH 
deficiency occurs in 75%(64). Replacement in pre-pubertal children is 
recommended and safe. Because radiotherapy is often adjuvant, pre-
irradiation endocrine deficits are common(65). Loss of previously present 
hormonal function after radiation is known and begins after 12months of 
treatment, growth hormone is the most frequently occurring. Onset is dose 
dependent while severity is influenced by dose per fraction. 
New neurological deficits: Vision deterioration after surgery is infrequent and 
influenced by preoperative deficit and a pre-chiasmatic tumour location. New 
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motor deficits are rare and when present are transient. Late effects of 
radiation therapy including carotid vessel occlusion are very uncommon. 
Hypothalamic and cognitive dysfunction: This is one of the most debilitating 
consequences among survivors. The hypothalamus has multiple functions in 
the body including control of circadian rhythm, regulation of the autonomic 
nervous system including sympathetic control of lipolysis. Symptoms of 
dysfunction include obesity, fatigue, behavioural changes, blood pressure, 
temperature and heart rate dysregulation. Rapid weight gain is the most 
frequent complication of hypothalamic dysfunction. In a review of childhood 
obesity after craniopharyngioma treatment, Rosenfield found a trend towards 
obesity over time, at diagnosis 17% were obese vs 46% at follow up(66). Qi et 
al found a close association between tumour location near the floor of the 
third ventricle and development of new obesity(67). Cognitive dysfunction is 
also more common in paediatric patients with craniopharyngiomas. 
Disturbances in memory, attention, impulse control and socialization are 
present. 
 
In an attempt to create a standardized metric or rating scale for pre and post-
operative function, a number of functional scales exist. Many are 
comprehensive but difficult to apply practically. De Vile described a 
comprehensive scale with multiple variables including endocrine dysfunction, 
vision status, neurological dysfunction and education, this was modified by 
Elliot et al(32,68). A more readily applicable scale however is one described 
by Wen et al, a scale that stratifies patient function into grades I-IV(69). Grade 
one being grossly normal and independent, IV being entirely dependent on 
self-care. Grade II includes independent patients with endocrine dysfunction 
and moderate visual impairment, while grade III denotes severe visual 
impairment with focal neurological dysfunction.  
 
In stratifying patients according to functional outcome scales, it is hoped that 
associations in time can be made between level of function and intervention 
received to help modify treatment accordingly. 
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    Chapter 2 
 
Methods 
Study Design 
This was a retrospective folder review of patients admitted at Red Cross 
Children’s and Groote Schuur Hospitals. Sources of data included databases 
from neurosurgery, radiation oncology, endocrinology and radiology. Where 
data were missing from these sources, folders were extracted for chart 
review. 
 
Patient selection 
Patients were selected according to an existing paediatric neurosurgery and 
oncology database according to diagnosis. Only patients below the age of 
fourteen years at diagnosis were included, in accordance to the admission 
age limit at the Children’s Hospital. Although adolescents fall under a general 
acceptance of paediatric care in most centres, the treatment of these at our 
institution falls under adult neurosurgery, so were not included. Patients who 
received primary treatment at other institutions and subsequently referred to 
us were included only if prior treatment information was available. Those with 
missing pretreatment data were excluded from analysis. Inclusion dates were 
from January 1995 to 31 December 2015, thus constituting a 20year review. 
 
Data collection 
The following data categories were collected: 
Demographics: age, sex 
Presenting Clinical Features: symptoms and sings, and admission endocrine 
findings. 
Imaging and Intervention: 
Pre-operative imaging: size was defined into ordinal categories (small, 
intermediate, large and giant), relationship of tumour to the hypothalamus and 
appearance (solid, cystic or mixed). Only MRI with sagittal images was used 
to assess the relationship of tumour to the hypothalamus. 
Post-operative imaging: quantifying extent of resection (CT/MRI) into Gross 
Total Resection (GTR), Subtotal Resection (STR) or Biopsy. 
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Type of surgery: placement of reservoir and method, craniotomy for resection 
and operative detail and operative complications (neurological and 
endocrinological).  
Surgical mortality was defined as death within 30 days of surgery. 
 
Long term follow up information was collected form the multidisciplinary clinic 
records in the radiation oncology department at Groote Schuur Hospital.  
 
Privacy and Confidentiality:  
All data were deidentified for analysis. 	
Statistical Analysis 
This is primarily a descriptive study. Descriptive statistics were used to 
characterize the total sample and compare presenting symptoms and 
endocrine function. Continuous variables are described using means 
(standard deviations) and medians (interquartile ranges) depending on their 
distribution. Categorical variables are presented as frequencies and 
percentages.  
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    Chapter 3 
 
Results 
Patient population 
A total of 41 patients were identified, with mean age at presentation of 84.2 
months, 57% were female. The age ranged from 1year to 13 years.  This was 
a limited age range owing to the exclusion of adolescents up to 18years who 
are treated at the adult hospital. The median follow up period was 83.5 
months. All patients had clinical examination to detect visual deficit but only 
31 patients had documented formal preoperative vision assessment by an 
ophthalmologist. Table 5 summarizes the presenting clinical features. 
 
Table 5: presenting features and examination findings as documented in 
clinical notes. 
 
Imaging 
Preoperative imaging prior to 2000 consisted of CT only. Imaging 
characteristics were obtained either from available images or printed 
radiologist reports with tumour dimensions. Thirty-four patients had adequate 
data for volume assessment. Figure 1 shows typical examples of 
hypothalamic invasion grading. There were 2 cases of intra-sella tumours, the 
remainder extended to the suprasellar space. Hydrocephalus occurred in 
43.9%. These findings are summarized in table 6. 
Admission	clinical	features	 n	(%)		Visual	deterioration	Headache	Acute	hydrocephalus	Short	stature	Disturbed	consciousness	Learning	difficulty	Motor	weakness	Cranial	nerve	abnormality	Seizures	Behavioural	problem	Obesity		
	23	(56)	23	(56)	18(43.9)	11(26)	6(14)	5(12.1)	5(12.1)	4(9)	3(7.3)	2	(4.8)	2	(4.8)	
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Table 6: Summary of MRI tumour characteristics. Hypothalamic involvement 
evaluated according to Sainte-Rose grading system(30). 	Tumour	size	(34	patients)	 n	(%)			Small	(<2cm)	Medium	(2-4cm)	Large	(2.1-6cm)	Giant	(>6cm)	
	2	(5.8)	16	(47)	5	(14.7)	11	(32.3)	
Tumour	consistency	(40)	 		Cystic	>50%	Solid	Mixed	
	26	(65)	3	(7.5)	11	(27.5)	
Hypothalamic	involvement		(31	MRIs)		Type	0	Type	I	Type	II	
			4	(12.9)	13	(41.9)	14	(45.1)		
Figure 1: gadolinium contrast enhanced mid-sagittal MRI scans of two 
different patients demonstrating two types of hypothalamic involvement a) 
moderate size cystic craniopharyngioma Sainte-Rose Type I, hypothalamus is 
displaced but visible (arrow), b) giant multicompartment tumour Type II, the 
hypothalamus is no longer visible. 	
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Surgical results 
All but 4 patients had attempted surgical resection. Of the four who were not 
operated on, 2 had small intra-sella tumour and were observed, 2 had 
Ommaya catheter insertion only with no resection attempt. These outcomes 
were dichotomized according to approach and extent of resection. Gross total 
resection (GTR) was defined as absence of visible enhancing tumour or 
capsule on post operative MRI or CT. The choice of surgical approach was 
also evaluated between traditional craniotomy (large hemi-coronal flap and 
subfrontal approach) and supraorbital keyhole craniotomy.  
 
A total of 36 patients had surgical resection, one patient’s surgical results 
were omitted as he was operated on at another institution and referred to us 
for adjuvant therapy. There were 3 who had biopsy alone, 29(80.5%) had 
subtotal resection, 4(11%) had gross total resection. Surgical approach could 
be determined in 28 cases, of which 17(60.7%) had traditional craniotomy vs 
11(39.2%) with the supraorbital keyhole approach. Of the four GTRs, two 
were through pterional approach and two through supraorbital keyhole. All of 
the supraorbital keyhole craniotomies were performed after 2002. Only two of 
the four GTR cases had evaluable images for preoperative hypothalamic 
involvement. One had Type 0 and another Type I. These were too few for 
statistical comparisons. We had no surgical mortalities, even with 
reoperations. Surgical mortality was defined as any death within 30 days post 
operatively. One case of post-operative blindness operated in year 2000 
occurred and one case of new post-operative motor weakness treated earliest 
in our series in 1995.  
 
Ommaya reservoirs were placed in 21 patients. In the early period these were 
usually placed stereotactically. Seven stereotactic placements earlier in our 
series utilizing a locally developed stereotactic device, the Cape Town 
Stereotactic Pointer (CTSP), which used a rigid tripod frame and co-ordinate 
system, included one failed stereotactic insertion that converted to direct 
microsurgical placement. A total of 9 insertions were microsurgical and 6 were 
endoscopic. The first endoscopic Ommaya reservoir insertion was in 2003. 
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Endoscopic insertions are performed transventricular through the standard 
coronal midpupillary burr hole with a rigid endoscope. Frameless optical 
navigation guidance is occasionally used, but cyst perforation is always under 
direct vision, with adequate enough puncture to allow only the catheter width. 
A contrast leak test 3 to 6 weeks after insertion is standard practice in our 
unit.  
 
Technique: Under aseptic technique and local anaesthetic, the Ommaya 
reservoir is aspirated to a minimum volume equal to the instillation volume. 
Dilute water soluble contrast is then injected into the reservoir, followed by CT 
scan. The test is passed if contrast is contained within the cyst wall and failed 
if there is spillage into the ventricles or subarachnoid space. Failure of leak 
test requires repeat procedure after another 6 weeks. Eight patients (19.5%) 
required ventriculo-peritoneal shunts, including one with bilateral catheters. 
This patient had bilateral shunts in 1998 prior to the introduction of 
endoscopy.  
 
Endocrine 
Table 7 summarises pre and postoperative endocrine findings. One patient 
had no preoperative endocrine data after initial surgery at an outside 
institution and another 3 had no long-term post-treatment endocrine data due 
to not following up at the MDT clinic. Results of 40 preoperative and 38 long-
term follow patients are presented. Preoperative DI was diagnosed in 17.5% 
of cases. Of the 33 patients without preoperative DI, 22(66.6%) developed 
early post-operative DI. This rate is comparable other series. The overall long-
term rate of DI at last follow up, after multimodality treatment and tumour 
recurrences, was 84.2%, (32 of the 38 patients with available data). 
 
Table 7: Hormonal profile before and after therapy. Three patients did not 
have adequate follow up data. 
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Growth and Growth Hormone  
Eighteen patients had growth and weight charting available at last follow up. 
The remainder either had no growth monitoring performed or no record 
available. Thirteen children had growth failure with age-matched height below 
the 5th centile; 12 were not on GH supplementation; 4 of 18 were classified as 
obese. Two patients in the series showed growth without growth hormone, 
plotting between the 50th- 75th centiles for age/gender. These same patients 
were however also significantly above the 95th centiles for weight. Four 
patients received GH supplementation, the earliest administered in 2004. All 
demonstrated good growth including 1 patient who began well below the 5th 
centile (figure 2). One patient received replacement for 5 years: However, 
multiple tumour recurrences prompted a cessation of treatment out of concern 
for the role of GH in inducing tumour regrowth. This patient demonstrated 
good growth velocity while on treatment (figure 2a). Among those with GH 
deficiency, hormonal replacement had a positive effect on growth velocity 
Figure 2b. Of note, because of the cost incurred with GH supplementation, 
GH is not easily available to all patients; special motivation is required.  
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Figure 2: catch up growth on commencement of GH but remains below 5th 
centile. 		
 
Figure 2a: Growth chart of a patient with GH deficiency, showing initial growth 
below standard deviations for age and gender. On initiation of GH the chart 
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shows catch up growth to -1 SD. Cessation of therapy due to recurrent tumour 
growth leads to plateau of growth curve. 		
 
Figure 2b: Gender matched comparative charts of growth in two patients with 
GH deficiency. Left) the chart of a patient with no GH replacement shows 
velocity significantly below SD for age and gender. Right) the chart of a 
patient demonstrating increased growth velocity after introduction of GH. 
 
Radiotherapy 
A total of 30 patients were treated with post-operative radiation therapy. Of 
the 11 patients who were not treated, 1 was observed after GTR and 
subsequently lost to follow up; 1 patient returned to an outside province and 
also lost to follow up. Two patients had small intrasellar tumours that were 
observed with no growth; 2 were sent to the referring institution with 
radiotherapy services but there was no data on treatment there. There were 4 
patients with decisions for observation after near total resection, these were 
recent and still show no progression, and a single patient who only received 
intracystic interferon with sustained tumour response. All cases received fully 
fractionated 3D conformal external beam radiotherapy on a Linear Accelerator 
(LINAC) machine. No patients received radiosurgery. A small number of 
patients were partially treated with protons, however the inconsistent 
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availability of such treatment meant that none received exclusive proton 
therapy for independent analysis. The mean dose was 53.8Gy, mean dose 
per fraction 1.8Gy; 20(66.6%) were treated as planned adjuvant therapy and 
10(33.3%) were treated at tumour recurrence.  
 
 The time to disease progression between patients treated with surgery alone 
vs surgery and planned adjuvant radiotherapy was marginally longer for the 
planned radiotherapy group. The mean time to progression between surgery 
only and surgery with planned adjuvant radiotherapy was 39.4 and 46 months 
respectively. This was most likely subject to selection bias, influenced by 
extent of surgical resection. Of the four patients who had imaging confirmed 
GTR, two had follow up data. One recurred at 22 months, the other at 65 
months after surgery alone. The two remaining patients did not follow up to 
the combined clinic. There were 2 early radiotherapy complications, both were 
transient alopecia, 5(16.6%) had late complications. The latter are listed in 
table 8. 
 
 
Table 8: radiotherapy complications. These were attributed to radiation if there 
was documented exclusion of recent surgery, hydrocephalus or disease 
progression after radiation treatment. 	
Intracystic Treament 
There has been an evolution in our intracystic therapy approach, driven by 
clinical experience and availability of newer, safer agents. Early in the series 
we used Yttrium 90. Only a single patient had available data after use of this 
	 Complication	 Time	from	radiotherapy		Patient	1	Patient	2	Patient	3			Patient	4		Patient	5	
	Seizures	Vision	deterioration	Transient	movement	disorder	Moyamoya	disease	Seizures	Cognitive	decline	GH/ACTH	deficiency	
	42	months	12	months	48	months		144	months	12	months	24	months	15	months	
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agent. This patient treated in 2001 developed late complications of DI and 
epilepsy, disease control was sustained for 36 months after which tumour cyst 
recurred.  
 
Six patients were treated with Bleomycin. Of these five had follow up data. 
Tumour control was modest, lasting 24, 36 and 38 months in three patients. 
One had complete resolution with no recurrence after Bleomycin was used as 
salvage therapy 76 months from initial surgery. However one patient suffered 
severe, fatal hypothalamic injury and prolonged coma after spillage of the 
agent into the ventricular system. Interferon has been used exclusively since 
then.  
 
Six cases were treated with interferon. In a single patient, the tumour cyst 
recurred 8 months after IF therapy. Another patient who received 3MUx5 
sessions (less than full course) had sustained cyst control up to the last follow 
up. This was at first recurrence 5 years after STR and 3 months following 
adjuvant radiotherapy. A single complication of transient lethargy and 
somnolence after instillation was noted. This was presumed a complication 
following spillage of the agent into the ventricular system; however the patient 
made a complete recovery. Table 9 summarises the patient details.  The 
standard protocol for Interferon at our institution consists of 3MU for 12 
sessions, totalling 36MU if tolerated, on an out patient basis. Each instillation 
is preceded by a minimum of 1.5-2ml aspiration of the reservoir to 
accommodate the 1ml drug instillation and 1ml flush. The cycle lasts 4 weeks. 
Interferon is currently the agent of choice at our institution.  
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 Dose Time from 
surgery 
(months) 
Salvage or 
Planned 
adjuvant 
Cyst 
Response 
Complication 
 
Patient 1 
 
 
Patient 2 
 
 
Patient 3 
 
 
Patient 4 
 
 
Patient 5 
 
 
Patient 6 
 
36 MU 
 
 
36 MU 
 
 
15 MU 
 
 
36 MU 
 
 
36 MU 
 
 
36 MU 
 
103 
 
 
83 
 
 
62 
 
 
6 
 
 
6 
 
 
5 
 
Salvage 
 
 
Salvage 
 
 
Salvage 
 
 
Adjuvant 
 
 
Adjuvant 
 
 
Adjuvant 
 
Controlled 
at 10 
months 
Controlled 
at 34 
months 
Controlled 
at 12 
months 
Recurrence 
at 8 
months 
Controlled 
at 16 
months 
Controlled 
at 6 
months 
 
Nil 
 
 
Somnolence 
Fatigue 
(transient) 
Nil 
 
 
Nil 
 
 
Nil 
 
 
Nil 
 Table	9:	a	summary	of	patients	treated	with	interferon	alpha	along	with	complications	and	cyst	response	at	the	last	follow	up	period.			
 
Functional outcome 
The four-tiered functional outcome scale by Wen (1989)(70) and colleagues 
was used to evaluate level of function at last follow up. Class I is grossly 
normal and independent, Class II independent but with panhypopituitarism 
and mild psychological dysfunction, Class III patients are partially dependent 
with serious visual impairment, neurological deficits including seizures and 
learning disabilities. Class IV entirely dependent on others for self-care. All 
patients are seen at a multidisciplinary clinic including paediatric 
neurosurgeons, medical and radiation oncologists, educational psychologist 
and paediatric endocrinologists.  At last follow up, 32 were still attending the 
follow up clinic: 7(21.8%) were Class I, 10(31.2%) Class II, 15(46.8%) Class 
III. No patients had Class IV function. However, only 13 had educational 
psychology evaluation reports. Of these, 6 had learning disability and were 
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not in mainstream school, 4 had normal IQ and were in normal school. Two 
patients were blind, receiving assisted schooling and one with very poor 
vision, also in assisted schooling.  
 
There were five deaths in our series and all were late occurrences. 
Table 10 summarises case mortalities and last documented follow up. All 
three of the patients who presented in endocrine crisis were from outside of 
the province and had missed multiple scheduled MDT clinic appointments 
before representing in extremis. While within the care of our system, control of 
DI and education of caregivers on DDAVP administration was good. 
Reintegration into the community, which is frequently remote and under 
resourced resulted in failure of adherence.  	Mortality	 Time	from	diagnosis	 Class	at	last	F/U	 Cause		2002	2001	2003		2005	2009	
	7y5m	6y	7y4m		6y	8y		
	Unknown	Class	III	Class	II		Class	III	Class	III	
	Unknown	Uncontrolled	DI	Unknown,	unexpected	Endocrine,	DI	Uncontrolled	DI	
Table 10: summary of mortalities reflecting severe DI crisis as important 
contributor to late mortality.		
Discussion 
Craniopharyngioma is a benign but locally aggressive tumour with a high 
propensity for recurrence. Recurrences have been associated with higher 
treatment related morbidity and mortality(71,72). However, although more 
aggressive surgical resection leads to reduced recurrence, it also leads to 
higher morbidity. The morbidity incurred by aggressive surgery is attributed to 
hypothalamic dysfunction from manipulation of the tumour capsule which is 
often adherent. Vascular injury, especially small perforator vessel disruption to 
the deep grey nuclei, internal capsule and the optic chiasm also can occur. 
This has lead to an evolution in management philosophy worldwide. 
Previously there was greater enthusiasm for aggressive complete resection; 
more recently a more cautious approach is often adopted, comprising 
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maximal safe resection and adjuvant radiotherapy in pursuit of better quality 
of life(4,30,43,49). Overall survival rates have been high - 3, 5 and 10 year 
survival being 97%, 96% and 93% respectively(51). This has followed 
improved treatment techniques, therapeutic agents with better side effect 
profile and advancements in surgical strategies. A few issues remain debated 
though. For example, some institutions still prefer more aggressive resection, 
arguing that the endocrinological morbidity can be managed. In this though, 
the context in which the child is managed is of critical importance, particularly 
if resource limitations in the environment lead to suboptimal endocrine 
support. The risks of failures in the system are demonstrated in our results.  
 
In this study, we evaluated our institutional experience with 
craniopharyngiomas to document evolution in treatment and patient 
outcomes. In this it is important to keep in mind the age range when 
comparing results to other series. Ours is predominantly a population of 
young children and the later peak of 14-16 year olds is missed. While most 
institutions included patients up to 18-21 years of age, we were limited to <14 
due to institutional policy. Controlling for age, the numbers	accrued over 
similar follow up periods (18-22years) were comparable(30,32,66,73). Some 
of the other differences likely relate to public education, quality of primary care 
in peripheral communities, referral patterns and late presentation. As the only 
specialised paediatric centre in the country, patient referrals frequently come 
from outside of the province, often with prolonged delays between symptom 
onset and specialist contact. Consequently we expect a higher incidence of 
large to giant tumours and advanced disease morbidity at presentation.  
Consistent with other series, headache and visual deterioration are the most 
frequently reported symptoms in the literature. In a series of 54 children with 
craniopharyngiomas, Tomita et al reported headaches and visual change in 
29 and 18 children respectively(74). Effenterre et al in a larger series of 122 
mixed adult and paediatric cases, found 75% of patients to have decreased 
vision as a presenting complaint(22). Poor vision and headache both 
accounted for 56% in our series consistent with this trend.  
Our data showed a high rate of preoperative hormonal deficits, particularly 
thyroid and adrenal hormone dysfunction. Preoperative GH was lower than 
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reported in other series. Muller et al reported a preoperative GH deficiency 
rate of 75%, with TSH and ACTH rates of 25% each(25). These findings were 
reversed in our series with higher ACTH, TSH rate 67.5% and lower GH. This 
is interesting however, considering that 26% of our children had pathological 
growth at diagnosis, which is in keeping with other institutional experiences. 
Preoperative DI was seen in 17.5% of patients, higher than generally 
reported, perhaps reflecting slightly larger volume tumours in our experience. 
 
Tumour volume is a predictor of extent of resection, degree of hypothalamic 
invasion and quality of life outcomes(28,33,75). In series with similar patient 
numbers, giant tumours constituted between 0,7% to 24% of the tumours 
imaged(75–77). Our rate of 32.3% was higher than usually reported. It would 
be expected that this would influence the rate of complete resection and 
radiation morbidity, given the larger treatment field that may need coverage. 
This along with a 45% incidence of hypothalamic invasion likely influenced the 
high STR rate. Unlike other centres, which have gone through periods of 
aggressive surgery and more cautious STR with RT, we have adopted a view 
of maximal safe resection followed by either surveillance or adjuvant 
radiotherapy. Similarly with our approach to insertion of Ommaya catheters, a 
retrospective series from Brazil found a comparable rate of complications 
independent of technique used for insertion(78). Over the years, our service 
has evolved away from frame-based stereotactic placement, to endoscopic 
placement of catheters.  
 
This evolution with improved technology and data availability is most apparent 
with the appreciation for the role of radiation therapy in achieving durable 
tumour control in subtotally resected tumours with a favourable side effect 
profile. Missing radiotherapy after subtotal resection emerged as a risk factor 
for early recurrence or progression(34,49,50,79–81). Improved planning and 
dose delivery technologies have helped improve long-term side effect profile. 
Charged particle therapy, usually protons has been suggested as a further 
improvement with favourable radiobiological profile for paediatric brain 
tumours(41,82). Although some of our patients received partial treatment with 
protons, none completed treatment without photon-based therapy, so no 
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meaningful assessment can be made on the efficacy. Our side effect profile 
was low with only single cases of visual deterioration, cognitive decline and 
moyamoya disease, which was diagnosed on imaging	but was asymptomatic. 
Delayed progressive hormonal loss is a well-known complication of radiation 
therapy. Growth hormone is most frequently affected, even at doses as low as 
18Gy, this can be as high as 50%-100%(83). We had one patient with such a 
complication, occurring at 15 months after receiving a dose of 54Gy in 
1,8Gy/fraction. Pre-radiation hormonal deficiencies are far more common 
however. 
 
In terms of intracystic treatments, we have evolved from Beta emitting 
isotopes (Yttrium 90) to Bleomycin, to Interferon Alpha. Consistent with 
emerging international results, we have found interferon to have a safer profile 
and tumour cyst control rates have not been inferior. The issue of what to do 
with planned Interferon instillation if there is contrast leakage from the cyst is 
an unresolved issue. Anecdotally, others have not reported significant side 
effects; however, we have been cautious because of our experience with one 
patient as described above.  
 
Endocrine 
An important outcome of our study is the significant role that endocrine 
dysfunction plays in the quality of life and survival of craniopharyngioma 
patients in the developing world setting. Our results raise health economic 
and health coverage issues. It emphasizes the necessity of multidisciplinarity 
and the need for endocrine surveillance, particularly when patients are from 
rural areas. Panhypopituitarism is the most common morbidity among 
craniopharyngioma survivors(84).  This correlates with a minimum of Class II 
Wen functional grade. Thyroid and adrenocortical replacement is widely 
available in South Africa but growth hormone is restricted due to cost. 
Significant motivation by paediatric endocrinology is required to have the 
agent available. Of our charted patients, a significant proportion were 
markedly growth restricted while objectively documented to be GH deficient. 
Equally, the positive effect of replacement on the height gain is evident in our 
data. Another indirect possible benefit of GH supplementation is on the 
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distribution of body fat. Obesity is a frequent consequence of disease and 
therapy, while cardiovascular related events are important contributors to late 
mortality and morbidity(66,67,85,86). GH is known to reduce total body fat, 
while this has not been correlated with reduced cardiovascular events, it may 
be of benefit against the likelihood of obesity in this group.  
 
Diabetes insipidus has accounted for all of the known cause mortalities in our 
series. Up to now, little tumour directed intervention has significantly reduced 
the incidence of this morbidity and the long-term risk remains high. The 
difficulty is when patients are referred for specialised treatments from remote 
centres and provinces without the ability to sustain the same standard of care 
or quality of surveillance. Patients may not be able to afford transport to a 
major centre for ongoing surveillance and/or may neglect to do so if the child 
is looking well. An additional difficulty is the multi-lingual culture in South 
Africa, often without equivalent words for specific medical terms. There is 
difficulty in communicating the meaning and importance of a hormone in some 
South African languages. Whether this is a contributor to the inability to 
sustain compliance with life sustaining hormonal replacement like DDAVP is 
uncertain but possible. Further work is required to determine the reasons for 
poor follow up in the patients who died.  
 
Limitations 
As a retrospective study, poor record keeping, incomplete data and medical 
records that were destroyed by hospital administration for inactive patients 
limited us. The latter has important considerations for long term chronic care 
management of patients, research and medicolegal concerns. Over a long 
period of time, we expect that several changes are likely made for treatment 
regimes, so comparisons of outcomes between patients early and late in the 
series are not straightforward. The age limit excluded adolescents who might 
express different clinical behaviour; this also limited the sample size and 
reduces comparability to other series. The outcomes also reflect a specialised 
centre with a small number of dedicated and experienced clinicians, which 
may not be generalizable to other centres. Limited data were available to 
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determine the precise conditions in which the late deaths occurred; therefore 
important contributing factors can only be surmised.  	
Conclusion 
The current study shows the complexity and heterogeneity of patients with 
craniopharyngioma, which requires multidisciplinary and individualised 
approaches to management. An evolution in approach and willingness to 
adopt newer modalities has allowed our results to be comparable to more 
resourced environments. Surgical morbidity and mortality is low and overall 
survival high with a cluster in the mild to moderate quality of life survival 
scores. Radiation therapy has proven to be safe and effective with low 
complication rates. Although our numbers were not large enough to clarify 
efficacy between planned adjuvant and salvage treatment timing. The local 
landscape of centralised care and risk of loss to follow up probably supports 
planned adjuvant fractionated radiation therapy to patients with residual solid 
tumour. However, the late deaths in our series highlight an important aspect 
of long-term care. Access to regular surveillance with endocrinological 
support, education of the family, and engagement with local health care 
providers are all critical factors that need greater attention if we are to avoid 
late morbidity and mortality. A further challenge is the limited availability of 
growth hormone in the public hospitals and the influence that this restriction 
has on adequate growth and development, as demonstrated in our series. It 
seems imperative that this drug be made available to children who 
demonstrate GH deficiency or growth restriction. Prescribing restricted to 
endocrinologists is a simple intervention to control cost. 
 
More than anything, our results again show the critical role of a multi-
disciplinary team approach to treatment of children with brain tumours. The 
value of this in our estimation is arguably greater than access to any specific 
new tools or therapies. Just as important, our results emphasize that 
childhood brain tumours and the consequences of treatment require a long 
term, chronic care approach that goes well beyond the acute cluster of 
therapies in the acute phase.  
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